Topotecan
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB01030 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 100 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | female breast carcinoma | KG + DL |
| 2 | adult germ cell tumor | KG + DL |
| 3 | testicular yolk sac tumor, solid pattern | KG + DL |
| 4 | polyvesicular vitelline pattern testicular yolk sac tumor | KG + DL |
| 5 | enteric pattern testicular yolk sac tumor | KG + DL |
| 6 | testicular yolk sac tumor, endodermal sinus pattern | KG + DL |
| 7 | testicular yolk sac tumor, papillary pattern | KG + DL |
| 8 | testicular yolk sac tumor, macrocystic pattern | KG + DL |
| 9 | reticular pattern testicular yolk sac tumor | KG + DL |
| 10 | testicular yolk sac tumor, hepatoid pattern | KG + DL |
| 11 | rectum mucinous adenocarcinoma | KG + DL |
| 12 | mediastinal malignant germ cell tumor | KG + DL |
| 13 | colon mucinous adenocarcinoma | KG + DL |
| 14 | childhood ovarian yolk sac tumor | KG + DL |
| 15 | ovarian yolk sac tumor, hepatoid pattern | KG + DL |
| 16 | ovarian yolk sac tumor, polyvesicular vitelline pattern | KG + DL |
| 17 | ovarian yolk sac tumor, glandular pattern | KG + DL |
| 18 | gallbladder mucinous adenocarcinoma | KG + DL |
| 19 | cervical mucinous adenocarcinoma | KG + DL |
| 20 | extrahepatic bile duct mucinous adenocarcinoma | KG + DL |
| 21 | ovarian cystadenocarcinoma | KG + DL |
| 22 | lung colloid adenocarcinoma | KG + DL |
| 23 | endometrial mucinous adenocarcinoma | KG + DL |
| 24 | rete ovarii adenocarcinoma | KG + DL |
| 25 | Krukenberg carcinoma | KG + DL |
| 26 | villoglandular endometrial endometrioid adenocarcinoma | KG + DL |
| 27 | endometrial mixed adenocarcinoma | KG + DL |
| 28 | mucin-rich endometrial endometrioid adenocarcinoma | KG + DL |
| 29 | secretory uterine corpus endometrioid adenocarcinoma | KG + DL |
| 30 | stage I endometrioid carcinoma | KG + DL |
| 31 | stage II endometrioid carcinoma | KG + DL |
| 32 | malignant struma ovarii | KG + DL |
| 33 | ovarian cystic teratoma | KG + DL |
| 34 | cervical endometrioid adenocarcinoma | KG + DL |
| 35 | ovarian biphasic or triphasic teratoma | KG + DL |
| 36 | ovarian mixed germ cell neoplasm | KG + DL |
| 37 | malignant teratoma | KG + DL |
| 38 | ovarian teratoma | KG + DL |
| 39 | breast-ovarian cancer, familial, susceptibility to | KG + DL |
| 40 | malignant germ cell tumor of cervix uteri | KG + DL |
| 41 | mixed germ cell tumor | KG + DL |
| 42 | pediatric ovarian germ cell tumor | KG + DL |
| 43 | gonadoblastoma | KG + DL |
| 44 | pulmonary artery choriocarcinoma | KG + DL |
| 45 | non-gestational ovarian choriocarcinoma | KG + DL |
| 46 | urethral valve | KG + DL |
| 47 | Koolen de Vries syndrome | KG + DL |
| 48 | endometrial clear cell adenocarcinoma | KG + DL |
| 49 | colorectal adenocarcinoma | KG + DL |
| 50 | choriocarcinoma (disease) | KG + DL |
(Showing top 50 of 100 predictions)
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.